Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2014 Financial Results
February 19 2015 - 6:00AM
Vical Incorporated (Nasdaq:VICL) today announced that the company
will report financial results for the three and twelve months ended
December 31, 2014, before the opening of trading on Thursday,
February 26, and conduct a conference call and webcast to discuss
the financial results and provide a company update at noon Eastern
Time on Thursday, February 26. The call will be open on a
listen-only basis to any interested parties. The company will also
provide a business update, including details on independent and
partnered development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten
minutes before the scheduled call to (719) 325-2244 (preferred), or
(888) 438-5453 (toll-free), and reference confirmation code
8639391. A replay of the call will be available for 48 hours
beginning about two hours after the call. To listen to the replay,
dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and
enter replay passcode 8639391. The call also will be available live
and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference
call. Others may submit questions before the call by e-mail
addressed to ir@vical.com or by fax to (858) 646-1150. Submitted
questions will be screened for appropriateness and general
interest. Selected questions received with sufficient notice before
the call will be answered as time permits at the end of the call.
For further information, contact Vical's Investor Relations
department by phone at (858) 646-1127 or by email at
ir@vical.com.
About Vical
Vical researches and develops biopharmaceutical products
leveraging its patented DNA delivery technologies for the
prevention and treatment of chronic or life-threatening infectious
diseases. In addition, the company has collaborations with major
pharmaceutical and biotechnology companies focused on addressing
significant unmet medical needs. Additional information on Vical is
available at www.vical.com.
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements
include statements about Vical's focus, collaborative partners,
product candidates, and development status. Risks and uncertainties
include whether any product candidates will be shown to be safe and
efficacious in clinical trials; the timing of clinical trials;
whether Vical or its collaborative partners will seek or gain
approval to market any product candidates; the dependence of the
company on its collaborative partners; and additional risks set
forth in the company's filings with the Securities and Exchange
Commission. These forward-looking statements represent the
company's judgment as of the date of this release. The company
disclaims, however, any intent or obligation to update these
forward-looking statements.
CONTACT: Andrew Hopkins
(858) 646-1127
Website: www.vical.com
Vical (NASDAQ:VICL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vical (NASDAQ:VICL)
Historical Stock Chart
From Apr 2023 to Apr 2024